TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 339283

Group type: EXPERIMENTAL
Intervention: 15(S)15-methyl prostaglandin F2alpha administered as a single intramuscular injection (0.6 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 15(S)15-methyl prostaglandin F2alpha administered as vaginal suppositories (1.0 or 1.5 mg per suppository)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intramuscular injection (Group I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vaginal suppositories (Group II)
Number of subjects: 30
Study: 30776918

Group type: EXPERIMENTAL
Intervention: Viewing an anxiety-inducing film fragment
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Giving a short presentation to an audience (impromptu speech task)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Watching another person's presentation (control condition)
Number of subjects: 277
Study: 30024027

Group type: EXPERIMENTAL
Intervention: Auricular point acupressure (APA) treatment along with sleep hygiene practices
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group receiving sleep hygiene practices alone
Number of subjects: 47
Study: 27067882

Group type: EXPERIMENTAL
Intervention: Real rTMS (5-Hz, 10 daily sessions)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 41
Study: 25391168

Group type: EXPERIMENTAL
Intervention: Probiotics (Infloran: Lactobacillus acidophilus 1 x 10(9) and Bifidobacterium bifidum 1 x 10(9) organisms) at a dose of 125 mg/kg/dose twice a day for 6 weeks or until discharge
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (breast milk or premature formula alone)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Probiotics (Infloran)
Number of subjects: 60
Study: 21925682

Group type: EXPERIMENTAL
Intervention: Amitifadine 25 mg BID for 2 weeks, then 50 mg BID for 4 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Amitifadine
Number of subjects: 63
Study: 20729253

Group type: EXPERIMENTAL
Intervention: Patient preference trial (CARPET1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Recruiting clinician's opinion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Surgeon preference
Number of subjects: 16
Study: 17507743

Group type: EXPERIMENTAL
Intervention: Carbohydrate loading (CHOL; 8.4 g x kg(‐1) x d(‐1) carbohydrate)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal diet (NORM; 5.2 g x kg(‐1) x d(‐1) carbohydrate)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal diet (NORM) in midfollicular (MF) phase
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carbohydrate loading (CHOL) in midfollicular (MF) phase
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carbohydrate loading (CHOL) in midluteal (ML) phase
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal diet (NORM) in midluteal (ML) phase
Number of subjects: 9
Study: 16268966

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg nocte
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 12766604

Group type: EXPERIMENTAL
Intervention: Renal transplant patients
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Patients without criteria of glomerular hyperfiltration
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Patients with glomerular hyperfiltration criteria
Number of subjects: 121
Study: 10327196

Group type: EXPERIMENTAL
Intervention: Walking (LEG)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propelling on a wheelchair (ARM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Verbally ordering a second person pushing the wheelchair (VERB)
Number of subjects: 8
Study: 8983335

Group type: EXPERIMENTAL
Intervention: Metyrapone (24 h treatment)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (24 h treatment)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (24 h treatment)
Number of subjects: 17
Study: 2054534

Group type: EXPERIMENTAL
Intervention: Tonic water plus vodka (approximately 0.05% blood alcohol level)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tonic water only
Number of subjects: 40
Study: 6295985

Group type: EXPERIMENTAL
Intervention: Antiovarian antiserum, colloidal P-32, delayed split whole abdominal irradiation, and maintenance melphalan
Number of subjects: 49

Group type: COMPARATOR
Intervention: Intraperitoneal antiserum and multiagent chemotherapy
Number of subjects: 49
Study: 6540685

Group type: EXPERIMENTAL
Intervention: Vindesine and cisplatin
Number of subjects: 105

Group type: COMPARATOR
Intervention: Vindesine alone
Number of subjects: 105
Study: 30805853

Group type: EXPERIMENTAL
Intervention: Resilient Families program
Number of subjects: 1826

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1826
Study: 25545117

Group type: EXPERIMENTAL
Intervention: High-income group (>$80K)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Moderate-income group ($40-80K)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Low-income group (<$40K)
Number of subjects: 320
Study: 25231803

Group type: EXPERIMENTAL
Intervention: Progressive Walking program (PW)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 37
Study: 22305828

Group type: EXPERIMENTAL
Intervention: Conventional drug-eluting stent (DES)
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: DES with biodegradable polymer
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS) with biocompatible coating
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Prasugrel-based antiplatelet therapy for 12 months
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Prasugrel-based antiplatelet therapy for 1 month (in stable patients with BMS)
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Secondary endpoints include stent thrombosis and major bleeding
Number of subjects: 2400
Study: 20226286

Group type: EXPERIMENTAL
Intervention: Ibandronate 150 mg/month
Number of subjects: 93
Study: 17668972

Group type: EXPERIMENTAL
Intervention: Automated flosser (A)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Manual floss (M)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 102
Study: 15814983

Group type: EXPERIMENTAL
Intervention: Pooling first-catch urine (FCU) specimens using Roche Amplicor PCR for C. trachomatis and N. gonorrhoeae
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Pooling first-catch urine (FCU) specimens
Number of subjects: 690

Group type: COMPARATOR
Intervention: Individual testing of FCU specimens
Number of subjects: 690
Study: 14571283

Group type: EXPERIMENTAL
Intervention: Formulation A: 2 x 500 mg paracetamol tablets (Laboratorios Belmac S.A.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formulation B: 1 x 1,000 mg paracetamol powder sachets (Laboratorios Belmac, S.A.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formulation C: 2 x 500 mg paracetamol film-coated tablets (Panadol, SmithKline Beecham)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formulation D: 2 x 500 mg paracetamol tablets (Tylenol, McNeil)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formulation E: 1 x 1,000 mg effervescent paracetamol tablets (Efferalgan, UPSA)
Number of subjects: 12
Study: 10645700

Group type: EXPERIMENTAL
Intervention: Diclofenac + Pitofenone + Fenpiverinium (Manyana)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Analgin + Pitofenone + Fenpiverinium (Baralgan)
Number of subjects: 200
Study: 8911223

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1872429

Group type: EXPERIMENTAL
Intervention: Triple nerve block (three in one block) with subcostal nerve block
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anaesthesia combined with opioid supplementation
Number of subjects: 50
Study: 6347752

Group type: EXPERIMENTAL
Intervention: Verapamil 200 mg b.i.d.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Verapamil 120 mg t.i.d.
Number of subjects: 8
Study: 31596819

Group type: EXPERIMENTAL
Intervention: NLP-based models (Model 4 with NLP 5-grams)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: NLP-based models (Model 7, combination of Models 1 and 4)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Administrative data only (Model 1)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: NLP-based models
Number of subjects: 372
Study: 28845898

Group type: COMPARATOR
Intervention: Venlafaxine ER 75-mg capsule before RYGB
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75-mg capsule after RYGB
Number of subjects: 10
Study: 25656305

Group type: EXPERIMENTAL
Intervention: LY2409021 (5, 30, 60 or 90mg) administered daily for 28 days to patients with type 2 diabetes
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: LY2409021 (single doses)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: LY2409021 (multiple dosing)
Number of subjects: 79
Study: 24347519

Group type: EXPERIMENTAL
Intervention: Epirubicin-docetaxel-capecitabine (EDC)
Number of subjects: 536
Study: 22869576

Group type: EXPERIMENTAL
Intervention: mericitabine plus danoprevir
Number of subjects: 73
Study: 19534829

Group type: EXPERIMENTAL
Intervention: RTP‐ASE Qontrast quantification
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Visual evaluation of ischaemia
Number of subjects: 67

Group type: COMPARATOR
Intervention: SPECT
Number of subjects: 67
Study: 17325311

Group type: EXPERIMENTAL
Intervention: Empower Youth Program (9-week intervention)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual school services
Number of subjects: 40
Study: 15611894

Group type: EXPERIMENTAL
Intervention: Shoulder‐head elevation pillow (SHEP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP) therapy
Number of subjects: 14
Study: 11586699

Group type: EXPERIMENTAL
Intervention: Zolpidem (ivadal) 10 mg once daily before sleep for 2 weeks
Number of subjects: 1017
Study: 10340198

Group type: EXPERIMENTAL
Intervention: 3‐h behavioural skills building intervention focused on educating women about the female condom, motivating use, and building relevant skills.
Number of subjects: 105

Group type: COMPARATOR
Intervention: Time-matched broadly defined women's health education intervention.
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 3‐h behavioural skills building intervention
Number of subjects: 105
Study: 8938533

Group type: EXPERIMENTAL
Intervention: Immunodeficient patients
Number of subjects: 13

Group type: COMPARATOR
Intervention: Immunocompetent patients
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Acute infection (immunodeficient)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Chronic infection (immunocompetent)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Chronic infection (immunodeficient)
Number of subjects: 13
Study: 1927064

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms twice daily after meals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NSAID treatment
Number of subjects: 0
Study: 6802080

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 0

Group type: COMPARATOR
Intervention: D-penicillamine
Number of subjects: 0
Study: 31860407

Group type: EXPERIMENTAL
Intervention: Intravenous glucocorticoids (IVGCs)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Oral glucocorticoids (OGCs)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 99
Study: 30572941

Group type: EXPERIMENTAL
Intervention: mhGAP-based training
Number of subjects: 18
Study: 26581718

Group type: EXPERIMENTAL
Intervention: DEX implant 0.7 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DEX implant 0.35 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0
Study: 24989138

Group type: EXPERIMENTAL
Intervention: IV tedizolid phosphate 100-400 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: IV tedizolid phosphate 200 mg once/day for 7 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Single oral dose of tedizolid phosphate 200 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: IV tedizolid phosphate 200 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 90
Study: 22030442

Group type: EXPERIMENTAL
Intervention: Purposeful activity group (PA-group, n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rote exercises group (Rex-group, n=15)
Number of subjects: 30
Study: 20113145

Group type: EXPERIMENTAL
Intervention: Resilient appliance therapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Non-occluding control appliance
Number of subjects: 73
Study: 17976724

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.5 mg) administered over a 2-year period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First-eye model of ranibizumab treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined model of ranibizumab treatment
Number of subjects: 0
Study: 15990632

Group type: EXPERIMENTAL
Intervention: High energy density feeds (oil added; caloric density = 35 kcal/100 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low energy density feeds (without oil; caloric density = 20 kcal/100 g)
Number of subjects: 20
Study: 12898763

Group type: EXPERIMENTAL
Intervention: ProFile nickel‐titanium rotary instruments
Number of subjects: 95

Group type: COMPARATOR
Intervention: Stainless steel hand files‐FlexoFile
Number of subjects: 95
Study: 10097838

Group type: EXPERIMENTAL
Intervention: Group therapy (10 sessions)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Individual therapy (10 sessions)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Both modalities
Number of subjects: 86
Study: 8835624

Group type: EXPERIMENTAL
Intervention: Intravenous atropine (0.03 mg/kg i.v.)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol (10-15 mg i.v.)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (placebo condition)
Number of subjects: 9
Study: 1596811

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment (thuya 30 CH, antimonium crudum 7 CH, nitricum acidum 7 CH)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 162
Study: 6586395

Group type: EXPERIMENTAL
Intervention: Intracervical PGE2 gel
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intraamniotic PGF(2a)
Number of subjects: 41
Study: 30327868

Group type: EXPERIMENTAL
Intervention: Wild blueberry drink (WBB)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 29506072

Group type: EXPERIMENTAL
Intervention: IPV/RC communication-skills building workshop
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Standard knowledge-based IPV/RC training
Number of subjects: 679

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 679
Study: 26906970

Group type: EXPERIMENTAL
Intervention: Smartphone website
Number of subjects: 161

Group type: COMPARATOR
Intervention: Leaflet
Number of subjects: 161
Study: 24952700

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 22309265

Group type: EXPERIMENTAL
Intervention: 5 mg iptakalim
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 mg iptakalim
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20 mg iptakalim
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5 mg iptakalim (women)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20 mg iptakalim (women)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5 mg iptakalim (men)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5 mg iptakalim (fasting and nonfasting)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5 mg, 10 mg, 20 mg iptakalim
Number of subjects: 16
Study: 20077478

Group type: EXPERIMENTAL
Intervention: 18 hours of clinic group rehabilitation plus 9 hours of attention control social sessions
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 27 hours of rehabilitation (18 in clinic group rehabilitation and 9 hours designed for home and community routines)
Number of subjects: 116

Group type: COMPARATOR
Intervention: 0 hours of rehabilitation
Number of subjects: 116
Study: 17822876

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus treatment
Number of subjects: 11
Study: 15641091

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 21
Study: 12704675

Group type: EXPERIMENTAL
Intervention: Screening arm (PSA testing)
Number of subjects: 14349

Group type: COMPARATOR
Intervention: Control arm (PSA testing)
Number of subjects: 14349
Study: 10568897

Group type: EXPERIMENTAL
Intervention: Sample size calculations based on statistical power for testing hypotheses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sample size methods based on ensuring accurate estimation of important parameters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methods and examples for sample size calculations for continuous and dichotomous outcomes
Number of subjects: 0
Study: 8740602

Group type: EXPERIMENTAL
Intervention: Cognitive self-hypnosis (CSH) treatment
Number of subjects: 144

Group type: COMPARATOR
Intervention: Autogenic training (AT)
Number of subjects: 144
Study: 8500238

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 743

Group type: COMPARATOR
Intervention: Hydralazine-isosorbide dinitrate
Number of subjects: 743
Study: 3481557

Group type: EXPERIMENTAL
Intervention: Combination of tumor markers (carcinoembryonic antigen, ferritin, cancer antigen 125, tissue polypeptide antigen)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Elevated characteristic value (greater than or equal to cut-off score)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Normal tumor marker profiles
Number of subjects: 109
Study: 30849021

Group type: EXPERIMENTAL
Intervention: Health education intervention (7-week class on health behaviors)
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 532

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 532
Study: 28914592

Group type: EXPERIMENTAL
Intervention: 0.2% HA gel
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.8% HA gel
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (periodontal dressing only)
Number of subjects: 36
Study: 27085637

Group type: EXPERIMENTAL
Intervention: Social network-based intervention promoting water consumption (n=106)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control condition (n=104)
Number of subjects: 210
Study: 25468576

Group type: EXPERIMENTAL
Intervention: Caudal 0.25% levobupivacaine (Group L(0.25))
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Caudal 0.20% levobupivacaine (Group L(0.20))
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Caudal 0.20% levobupivacaine plus 2 μg/kg dexmedetomidine (Group LD)
Number of subjects: 212
Study: 24041817

Group type: EXPERIMENTAL
Intervention: Former IDA children
Number of subjects: 47

Group type: COMPARATOR
Intervention: Non-anemic children
Number of subjects: 47
Study: 22289528

Group type: EXPERIMENTAL
Intervention: Combination of celecoxib and FOLFOX4 regimen (folinic acid‐fluorouracil‐oxaliplatin)
Number of subjects: 90

Group type: COMPARATOR
Intervention: FOLFOX4 regimen alone
Number of subjects: 90
Study: 19358502

Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion combined with amitriptyline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Amitriptyline alone
Number of subjects: 60
Study: 16638737

Group type: EXPERIMENTAL
Intervention: CS‐706 (2‐ to 800‐mg doses daily, up to 14 days)
Number of subjects: 130
Study: 15580062

Group type: EXPERIMENTAL
Intervention: 200 ml meal rich in fat
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 200 ml meal rich in carbohydrate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 200 ml meal rich in protein
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fasting exercise test
Number of subjects: 20
Study: 11298548

Group type: EXPERIMENTAL
Intervention: Oral terbinafine 250 mg daily (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (moisturizing ointment) (n = 30)
Number of subjects: 60
Study: 11233189

Group type: EXPERIMENTAL
Intervention: Pacemaker (DDD) treatment
Number of subjects: 83

Group type: COMPARATOR
Intervention: Sham phase
Number of subjects: 83
Study: 8003095

Group type: EXPERIMENTAL
Intervention: DHEAS levels in cases
Number of subjects: 159

Group type: COMPARATOR
Intervention: DHEAS levels
Number of subjects: 159
Study: 2573727

Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 6
Study: 4817683

Group type: EXPERIMENTAL
Intervention: Physiotherapy supervised by a physiotherapist
Number of subjects: 96

Group type: COMPARATOR
Intervention: Mobilization headed by a physician with written and oral instructions
Number of subjects: 96
Study: 29550650

Group type: EXPERIMENTAL
Intervention: 1 W/kg (Low RF)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2 W/kg (High RF)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0 W/kg (Sham)
Number of subjects: 36
Study: 24515943

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri 10^8 organisms once daily for 5 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (identical appearing)
Number of subjects: 45
Study: 20661272

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 331
Study: 20976769

Group type: EXPERIMENTAL
Intervention: B-vitamins (daily folic acid 2 mg, vitamin B6 25 mg, vitamin B12 0.5 mg)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study: 19156097

Group type: EXPERIMENTAL
Intervention: Modified Bascom method
Number of subjects: 96

Group type: COMPARATOR
Intervention: Traditional method of coccygeal duct excision and wound closure
Number of subjects: 96
Study: 15722810

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation (rheumatologist and physical therapist intake and discharge, 18 group supervised exercise therapy sessions, 2 group pain and stress management lectures, 1 group education lecture, 1 group dietary lecture, and 2 massage therapy sessions)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard medical care with the patients' family physician
Number of subjects: 79
Study: 12535870

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15